nodes	percent_of_prediction	percent_of_DWPC	metapath
Metocurine—Tubocurarine—ACHE—prostate cancer	0.493	0.558	CrCbGaD
Metocurine—Tubocurarine—SLC22A1—prostate cancer	0.391	0.442	CrCbGaD
Metocurine—CHRNA1—Neuronal System—COMT—prostate cancer	0.00045	0.00387	CbGpPWpGaD
Metocurine—CHRM2—G alpha (i) signalling events—PENK—prostate cancer	0.000449	0.00386	CbGpPWpGaD
Metocurine—CHRNA2—Neuronal System—COMT—prostate cancer	0.000427	0.00368	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—RLN2—prostate cancer	0.000422	0.00363	CbGpPWpGaD
Metocurine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—prostate cancer	0.000418	0.00359	CbGpPWpGaD
Metocurine—CHRM2—Calcium Regulation in the Cardiac Cell—PRKACB—prostate cancer	0.000407	0.00351	CbGpPWpGaD
Metocurine—CHRM2—Class A/1 (Rhodopsin-like receptors)—MC2R—prostate cancer	0.0004	0.00344	CbGpPWpGaD
Metocurine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—prostate cancer	0.000397	0.00341	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—PRKACB—prostate cancer	0.000393	0.00338	CbGpPWpGaD
Metocurine—CHRM2—Calcium Regulation in the Cardiac Cell—PRKCZ—prostate cancer	0.000384	0.00331	CbGpPWpGaD
Metocurine—CHRM2—Calcium Regulation in the Cardiac Cell—CALR—prostate cancer	0.000377	0.00325	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—GRPR—prostate cancer	0.000371	0.00319	CbGpPWpGaD
Metocurine—CHRM2—Regulation of Actin Cytoskeleton—FGFR4—prostate cancer	0.000371	0.00319	CbGpPWpGaD
Metocurine—CHRM2—G alpha (i) signalling events—LPAR1—prostate cancer	0.00037	0.00318	CbGpPWpGaD
Metocurine—CHRND—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000369	0.00318	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—IL1RN—prostate cancer	0.000365	0.00314	CbGpPWpGaD
Metocurine—CHRM2—Class A/1 (Rhodopsin-like receptors)—PENK—prostate cancer	0.000357	0.00307	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—ESR2—prostate cancer	0.000339	0.00291	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—TH—prostate cancer	0.000336	0.00289	CbGpPWpGaD
Metocurine—CHRM2—G alpha (i) signalling events—GNG5—prostate cancer	0.000332	0.00286	CbGpPWpGaD
Metocurine—CHRM2—Calcium Regulation in the Cardiac Cell—PRKCQ—prostate cancer	0.000327	0.00281	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—WNT4—prostate cancer	0.00032	0.00275	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—EGR1—prostate cancer	0.000317	0.00273	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—OR51E2—prostate cancer	0.000314	0.00271	CbGpPWpGaD
Metocurine—CHRNA1—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000314	0.0027	CbGpPWpGaD
Metocurine—CHRM2—Calcium Regulation in the Cardiac Cell—GJA1—prostate cancer	0.000313	0.00269	CbGpPWpGaD
Metocurine—CHRM2—Regulation of Actin Cytoskeleton—FGF10—prostate cancer	0.00031	0.00267	CbGpPWpGaD
Metocurine—CHRM2—Calcium Regulation in the Cardiac Cell—ADRB2—prostate cancer	0.000307	0.00264	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—MC2R—prostate cancer	0.000305	0.00262	CbGpPWpGaD
Metocurine—CHRM2—Class A/1 (Rhodopsin-like receptors)—GNRH1—prostate cancer	0.000303	0.00261	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—GJA1—prostate cancer	0.000302	0.0026	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—AR—prostate cancer	0.000299	0.00257	CbGpPWpGaD
Metocurine—CHRNA2—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000298	0.00257	CbGpPWpGaD
Metocurine—CHRM2—Class A/1 (Rhodopsin-like receptors)—LPAR1—prostate cancer	0.000294	0.00253	CbGpPWpGaD
Metocurine—CHRM2—Class A/1 (Rhodopsin-like receptors)—GRP—prostate cancer	0.000294	0.00253	CbGpPWpGaD
Metocurine—CHRM2—Calcium Regulation in the Cardiac Cell—ITPR1—prostate cancer	0.000291	0.0025	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—OR51E2—prostate cancer	0.000286	0.00246	CbGpPWpGaD
Metocurine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CX3CL1—prostate cancer	0.000285	0.00245	CbGpPWpGaD
Metocurine—CHRND—Neuronal System—MDM2—prostate cancer	0.000283	0.00244	CbGpPWpGaD
Metocurine—CHRM2—G alpha (i) signalling events—ANXA1—prostate cancer	0.000272	0.00234	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—PENK—prostate cancer	0.000272	0.00234	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—RGS17—prostate cancer	0.000267	0.0023	CbGpPWpGaD
Metocurine—CHRM2—Regulation of Actin Cytoskeleton—PDGFRB—prostate cancer	0.000264	0.00227	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—IL10—prostate cancer	0.000262	0.00225	CbGpPWpGaD
Metocurine—CHRM2—Regulation of Actin Cytoskeleton—FGFR2—prostate cancer	0.000249	0.00214	CbGpPWpGaD
Metocurine—CHRM2—G alpha (i) signalling events—CXCL12—prostate cancer	0.000249	0.00214	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—RGS17—prostate cancer	0.000243	0.00209	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—NR3C1—prostate cancer	0.000242	0.00208	CbGpPWpGaD
Metocurine—CHRNA1—Neuronal System—MDM2—prostate cancer	0.000241	0.00207	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—RLN2—prostate cancer	0.000238	0.00205	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—GNRH1—prostate cancer	0.000231	0.00199	CbGpPWpGaD
Metocurine—CHRNA2—Neuronal System—MDM2—prostate cancer	0.000229	0.00197	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—GRP—prostate cancer	0.000224	0.00193	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—LPAR1—prostate cancer	0.000224	0.00193	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—HIF1A—prostate cancer	0.00022	0.0019	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—PLXNB1—prostate cancer	0.000218	0.00188	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—CX3CL1—prostate cancer	0.000217	0.00187	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—RLN2—prostate cancer	0.000216	0.00186	CbGpPWpGaD
Metocurine—CHRM2—Class A/1 (Rhodopsin-like receptors)—ANXA1—prostate cancer	0.000216	0.00186	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—GRPR—prostate cancer	0.00021	0.0018	CbGpPWpGaD
Metocurine—CHRM2—Regulation of Actin Cytoskeleton—PIK3CG—prostate cancer	0.000201	0.00173	CbGpPWpGaD
Metocurine—CHRM2—Regulation of Actin Cytoskeleton—APC—prostate cancer	0.000201	0.00173	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—GNG5—prostate cancer	0.000201	0.00173	CbGpPWpGaD
Metocurine—CHRM2—Regulation of Actin Cytoskeleton—EGF—prostate cancer	0.000199	0.00171	CbGpPWpGaD
Metocurine—CHRM2—GPCRs, Class A Rhodopsin-like—ADRB2—prostate cancer	0.000198	0.0017	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—PLXNB1—prostate cancer	0.000198	0.0017	CbGpPWpGaD
Metocurine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL12—prostate cancer	0.000198	0.0017	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—GRPR—prostate cancer	0.00019	0.00164	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—CREBBP—prostate cancer	0.00018	0.00155	CbGpPWpGaD
Metocurine—CHRM2—Regulation of Actin Cytoskeleton—MAP2K1—prostate cancer	0.000178	0.00153	CbGpPWpGaD
Metocurine—CHRM2—Regulation of Actin Cytoskeleton—PIK3CD—prostate cancer	0.000177	0.00152	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—PTHLH—prostate cancer	0.000175	0.00151	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—MC2R—prostate cancer	0.000172	0.00148	CbGpPWpGaD
Metocurine—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRB2—prostate cancer	0.00017	0.00146	CbGpPWpGaD
Metocurine—CHRM2—Regulation of Actin Cytoskeleton—FGF2—prostate cancer	0.00017	0.00146	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—OR51E2—prostate cancer	0.000169	0.00145	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—ANXA1—prostate cancer	0.000165	0.00142	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—WNT4—prostate cancer	0.000164	0.00141	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—MC2R—prostate cancer	0.000156	0.00135	CbGpPWpGaD
Metocurine—CHRM2—Regulation of Actin Cytoskeleton—PIK3CB—prostate cancer	0.000154	0.00133	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—BMPR1B—prostate cancer	0.000154	0.00133	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—CALCA—prostate cancer	0.000154	0.00133	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—PENK—prostate cancer	0.000154	0.00132	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—CXCL12—prostate cancer	0.000151	0.0013	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—RGS17—prostate cancer	0.000143	0.00123	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—CXCL8—prostate cancer	0.000143	0.00123	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—PENK—prostate cancer	0.000139	0.0012	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—CASP3—prostate cancer	0.000137	0.00118	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—CTNNB1—prostate cancer	0.000132	0.00114	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—VIP—prostate cancer	0.000131	0.00112	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—GNRH1—prostate cancer	0.000131	0.00112	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—ADRB2—prostate cancer	0.000129	0.00111	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—RLN2—prostate cancer	0.000128	0.0011	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—LPAR1—prostate cancer	0.000126	0.00109	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—GRP—prostate cancer	0.000126	0.00109	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—PLCB2—prostate cancer	0.000125	0.00108	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—EP300—prostate cancer	0.000123	0.00106	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—CTBP2—prostate cancer	0.000122	0.00105	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—HSD17B1—prostate cancer	0.000122	0.00105	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—PDE4D—prostate cancer	0.000119	0.00103	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—GNRH1—prostate cancer	0.000119	0.00102	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—VIP—prostate cancer	0.000119	0.00102	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PLXNB1—prostate cancer	0.000117	0.00101	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—VEGFA—prostate cancer	0.000116	0.000999	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—LPAR1—prostate cancer	0.000115	0.000988	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—GRP—prostate cancer	0.000115	0.000988	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—PLCB2—prostate cancer	0.000114	0.000978	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—GNG5—prostate cancer	0.000114	0.000977	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—GRPR—prostate cancer	0.000113	0.000968	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—CX3CL1—prostate cancer	0.000111	0.000959	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—IL17RD—prostate cancer	0.000109	0.000935	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—PDE4D—prostate cancer	0.000108	0.000933	CbGpPWpGaD
Metocurine—CHRM2—Regulation of Actin Cytoskeleton—EGFR—prostate cancer	0.000108	0.000933	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—GNG5—prostate cancer	0.000103	0.000887	CbGpPWpGaD
Metocurine—CHRM2—G alpha (i) signalling events—CXCL8—prostate cancer	0.000103	0.000887	CbGpPWpGaD
Metocurine—CHRM2—Regulation of Actin Cytoskeleton—KRAS—prostate cancer	0.000102	0.000881	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—PTHLH—prostate cancer	9.89e-05	0.000851	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—WNT4—prostate cancer	9.69e-05	0.000833	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—JUP—prostate cancer	9.69e-05	0.000833	CbGpPWpGaD
Metocurine—CHRM2—Regulation of Actin Cytoskeleton—PIK3CA—prostate cancer	9.41e-05	0.00081	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—ANXA1—prostate cancer	9.3e-05	0.0008	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—RALBP1—prostate cancer	9.24e-05	0.000795	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—MC2R—prostate cancer	9.24e-05	0.000795	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—PTHLH—prostate cancer	8.98e-05	0.000773	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—PRKACB—prostate cancer	8.79e-05	0.000757	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—CALCA—prostate cancer	8.71e-05	0.000749	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—PPP3CA—prostate cancer	8.57e-05	0.000737	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—CXCL12—prostate cancer	8.51e-05	0.000732	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—ANXA1—prostate cancer	8.45e-05	0.000727	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PENK—prostate cancer	8.24e-05	0.000709	CbGpPWpGaD
Metocurine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	8.19e-05	0.000705	CbGpPWpGaD
Metocurine—CHRM2—SIDS Susceptibility Pathways—IL6—prostate cancer	8.03e-05	0.000691	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—CALCA—prostate cancer	7.91e-05	0.000681	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—GHR—prostate cancer	7.86e-05	0.000676	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—PRKCQ—prostate cancer	7.76e-05	0.000668	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—CXCL12—prostate cancer	7.73e-05	0.000665	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—NRP1—prostate cancer	7.53e-05	0.000648	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—ADRB2—prostate cancer	7.3e-05	0.000628	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—VAV3—prostate cancer	7.12e-05	0.000612	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—PRKCQ—prostate cancer	7.05e-05	0.000607	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—VIP—prostate cancer	7e-05	0.000603	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—GNRH1—prostate cancer	7e-05	0.000603	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—ITPR1—prostate cancer	6.9e-05	0.000594	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—LPAR1—prostate cancer	6.78e-05	0.000584	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—GRP—prostate cancer	6.78e-05	0.000584	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—LRP2—prostate cancer	6.71e-05	0.000578	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PLCB2—prostate cancer	6.71e-05	0.000578	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—ADRB2—prostate cancer	6.63e-05	0.00057	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—CX3CL1—prostate cancer	6.58e-05	0.000567	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—P4HB—prostate cancer	6.58e-05	0.000567	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—VAV3—prostate cancer	6.46e-05	0.000556	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—HIST1H2BG—prostate cancer	6.46e-05	0.000556	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PDE4D—prostate cancer	6.41e-05	0.000551	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—GRB7—prostate cancer	6.41e-05	0.000551	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—ITPR1—prostate cancer	6.27e-05	0.000539	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—HIST1H4H—prostate cancer	6.24e-05	0.000537	CbGpPWpGaD
Metocurine—CHRM2—GPCR ligand binding—CXCL8—prostate cancer	6.24e-05	0.000537	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—GNG5—prostate cancer	6.09e-05	0.000524	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PTHLH—prostate cancer	5.31e-05	0.000457	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—TGFBR1—prostate cancer	5.31e-05	0.000457	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—AKR1C3—prostate cancer	5.22e-05	0.000449	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PRKACB—prostate cancer	5.19e-05	0.000447	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—THBS1—prostate cancer	5.06e-05	0.000436	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PPP3CA—prostate cancer	5.06e-05	0.000436	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—ANXA1—prostate cancer	4.99e-05	0.000429	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PRKCZ—prostate cancer	4.9e-05	0.000421	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—PIK3CG—prostate cancer	4.79e-05	0.000412	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—FGFR4—prostate cancer	4.73e-05	0.000407	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PARP1—prostate cancer	4.73e-05	0.000407	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—CALCA—prostate cancer	4.67e-05	0.000402	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—CXCL12—prostate cancer	4.56e-05	0.000393	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—PIK3CG—prostate cancer	4.35e-05	0.000374	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—CASP9—prostate cancer	4.3e-05	0.00037	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—PIK3CD—prostate cancer	4.21e-05	0.000362	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PRKCQ—prostate cancer	4.16e-05	0.000358	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—NGFR—prostate cancer	4.16e-05	0.000358	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—MAP3K7—prostate cancer	4.12e-05	0.000354	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—FGF10—prostate cancer	3.96e-05	0.00034	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—ADRB2—prostate cancer	3.92e-05	0.000337	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—JAK2—prostate cancer	3.86e-05	0.000332	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—MAP2K1—prostate cancer	3.85e-05	0.000331	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—PIK3CD—prostate cancer	3.82e-05	0.000329	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—VAV3—prostate cancer	3.82e-05	0.000329	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—TGFBR2—prostate cancer	3.76e-05	0.000324	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—ITPR1—prostate cancer	3.7e-05	0.000319	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—PIK3CB—prostate cancer	3.67e-05	0.000316	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—IGF1R—prostate cancer	3.54e-05	0.000305	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—CXCL8—prostate cancer	3.53e-05	0.000303	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—JAK2—prostate cancer	3.51e-05	0.000302	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—LPL—prostate cancer	3.4e-05	0.000292	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—IL2—prostate cancer	3.37e-05	0.00029	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PDGFRB—prostate cancer	3.36e-05	0.00029	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—PIK3CB—prostate cancer	3.33e-05	0.000287	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—ITGB3—prostate cancer	3.28e-05	0.000282	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—CXCL8—prostate cancer	3.2e-05	0.000275	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—ERBB3—prostate cancer	3.18e-05	0.000274	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—FGFR2—prostate cancer	3.18e-05	0.000273	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—IL2—prostate cancer	3.06e-05	0.000263	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—TERT—prostate cancer	3.05e-05	0.000262	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—HIF1A—prostate cancer	2.92e-05	0.000251	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—LEP—prostate cancer	2.85e-05	0.000245	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—CAV1—prostate cancer	2.82e-05	0.000243	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—KDR—prostate cancer	2.79e-05	0.00024	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—ESR1—prostate cancer	2.72e-05	0.000234	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—BAD—prostate cancer	2.65e-05	0.000228	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PIK3CG—prostate cancer	2.57e-05	0.000221	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—APC—prostate cancer	2.57e-05	0.000221	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—EGF—prostate cancer	2.54e-05	0.000218	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—IRS1—prostate cancer	2.54e-05	0.000218	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—GSK3B—prostate cancer	2.46e-05	0.000212	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—INS—prostate cancer	2.43e-05	0.000209	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—CREBBP—prostate cancer	2.38e-05	0.000205	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—IGF1—prostate cancer	2.35e-05	0.000202	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—EGFR—prostate cancer	2.34e-05	0.000201	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	2.27e-05	0.000196	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	2.26e-05	0.000194	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	2.24e-05	0.000192	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	2.23e-05	0.000192	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—KRAS—prostate cancer	2.21e-05	0.00019	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—FGF2—prostate cancer	2.16e-05	0.000186	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—NOS3—prostate cancer	2.13e-05	0.000183	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—JAK2—prostate cancer	2.07e-05	0.000178	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	2.03e-05	0.000175	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—MDM2—prostate cancer	2.02e-05	0.000174	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—ERBB2—prostate cancer	1.99e-05	0.000172	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	1.97e-05	0.000169	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—CXCL8—prostate cancer	1.89e-05	0.000163	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	1.85e-05	0.000159	CbGpPWpGaD
Metocurine—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	1.83e-05	0.000157	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—CASP3—prostate cancer	1.81e-05	0.000156	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—IL2—prostate cancer	1.81e-05	0.000156	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—IL6—prostate cancer	1.8e-05	0.000155	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—CCND1—prostate cancer	1.76e-05	0.000152	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	1.74e-05	0.00015	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—MMP9—prostate cancer	1.71e-05	0.000147	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	1.7e-05	0.000147	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PTEN—prostate cancer	1.7e-05	0.000146	CbGpPWpGaD
Metocurine—CHRM2—Signaling by GPCR—AKT1—prostate cancer	1.66e-05	0.000143	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—EP300—prostate cancer	1.62e-05	0.00014	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—SRC—prostate cancer	1.58e-05	0.000136	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—VEGFA—prostate cancer	1.54e-05	0.000132	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—STAT3—prostate cancer	1.52e-05	0.000131	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—MYC—prostate cancer	1.41e-05	0.000122	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—TGFB1—prostate cancer	1.41e-05	0.000121	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—EGFR—prostate cancer	1.38e-05	0.000119	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—KRAS—prostate cancer	1.31e-05	0.000112	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	1.2e-05	0.000103	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—TP53—prostate cancer	1.16e-05	9.99e-05	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—IL6—prostate cancer	1.06e-05	9.14e-05	CbGpPWpGaD
Metocurine—CHRM2—Signaling Pathways—AKT1—prostate cancer	9.8e-06	8.43e-05	CbGpPWpGaD
